Jonathan Talbot
Hoffmann-La Roche
8 Papers
5 Citations
Jonathan Talbot is an academic researcher from Hoffmann-La Roche. The author has contributed to research in topics: Medicine & Atezolizumab. The author has an hindex of 4, co-authored 7 publications.
Chat about Author
Papers
Perioperative atezolizumab in combination with FLOT versus FLOT alone in patients with resectable esophagogastric adenocarcinoma: DANTE, a randomized, open-label phase II trial of the German Gastric Group of the AIO and the SAKK.
Salah-Eddin Al-Batran,Claudia Pauligk,Ralf Hofheinz,Sylvie Lorenzen,Andreas Wicki,Alexander Rheinhard Siebenhuener,Michael Schenk,Manfred Welslau,Vera Heuer,Eray Goekkurt,Harald Schmalenberg,Peter C. Thuss-Patience,Lisa Waberer,Jonathan Talbot,Thorsten Oliver Goetze,Nils Homann +15 more
TL;DR: Perioperative FLOT chemotherapy has become a standard of care for locally advanced, resectable gastric cancer and adenocarcinoma of the GEJ, but patient outcomes are still poor.
22
Interim safety analysis of the DANTE trial: Perioperative atezolizumab in combination with FLOT versus FLOT alone in patients with resectable esophagogastric adenocarcinoma—A randomized, open-label phase II trial of the German Gastric Group at the AIO and SAKK.
Nils Homann,Sylvie Lorenzen,Michael Schenk,Peter C. Thuss-Patience,Eray Goekkurt,Ralf Hofheinz,Albrecht Kretzschmar,Claus Bolling,S. Angermeier,Andreas Wicki,Alexander Rheinhard Siebenhuener,U. Lindig,Daniel Pink,Thomas J. Ettrich,Harald Schmalenberg,Lisa Waberer,Jonathan Talbot,Claudia Pauligk,Thorsten Oliver Goetze,Salah-Eddin Al-Batran +19 more
TL;DR: The DANTE study evaluates atezolizumab in the perioperative treatment of locally advanced, potentially resectable gastric or GEJ adenocarcinoma in combination with peri operative FLO...
14
A Systematic Review of the Clinical Efficacy of Treatments in Relapsed or Refractory Diffuse Large B Cell Lymphoma
TL;DR: The paucity of published RCTs to establish the comparative efficacy of treatments for transplant-ineligible R/R DLBCL and lack of standard of care in this setting are highlighted.
Perioperative atezolizumab in combination with FLOT versus FLOT alone in patients with resectable esophagogastric adenocarcinoma: DANTE, a randomized, open-label phase II trial of the German Gastric Group of the AIO and the SAKK
S-E. Al-Batran,Claudia Pauligk,R.D. Hofheinz,Sylvie Lorenzen,Andreas Wicki,Alexander Rheinhard Siebenhuener,Michael Schenk,Peter C. Thuss-Patience,A. Kretzschmar,Claus Bolling,E. Eigendorff,S. Angermeier,Daniel Pink,Michael Geissler,Eray Goekkurt,Harald Schmalenberg,Lisa Waberer,Jonathan Talbot,Thorsten Oliver Goetze,Nils Homann +19 more
TL;DR: This study evaluates atezolizumab in the perioperative treatment of locally advanced, potentially resectable gastric or GEJ adenocarcinoma in combination with FLOT, a PD-L1 inhibitor with established efficacy and tolerability profiles.
10
Safety of perioperative atezolizumab in combination with FLOT versus FLOT alone in patients with resectable esophagogastric adenocarcinoma: An interim safety analysis of the DANTE, a randomized, open-label phase II trial of the German Gastric Group at the AIO and the SAKK.
Salah-Eddin Al-Batran,Sylvie Lorenzen,Michael Schenk,Peter C. Thuss-Patience,Eray Goekkurt,Ralf Hofheinz,Albrecht Kretzschmar,Claus Bolling,S. Angermeier,Andreas Wicki,Alexander Rheinhard Siebenhuener,Ekkehard Eigendorff,Christin Pink,Thomas J. Ettrich,Harald Schmalenberg,Lisa Waberer,Jonathan Talbot,Claudia Pauligk,Thorsten Oliver Goetze,Nils Homann +19 more
TL;DR: In this article, the authors evaluated atezolizumab in the perioperative treatment of locally advanced, potentially resectable gastric or GEJ adenocarcinoma in combination with FLOT.
7